Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
Stock Information for Soleno Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.